Inflammatory bowel disease therapy: an update.
Compr Ther
; 21(6): 296-302, 1995 Jun.
Article
em En
| MEDLINE
| ID: mdl-7664541
ABSTRACT
The armamentarium for the treatment of IBD has grown considerably within the last decade. Sulfasalazine and corticosteroids, the two cornerstones of past therapy, are now joined by the 5-ASA drugs, antibiotics, immunosuppressive agents, and newer corticosteroids. In addition, several novel therapies with promising initial results are being investigated. As the mechanisms by which these agents work are elucidated, further insight into the pathogenesis of IBD will be gained. Based on the nature and extent of disease, physicians and patients will be able to select the optimal agent or therapeutic combination for control of this enigmatic and morbid disease.
Buscar no Google
Bases de dados:
MEDLINE
Assunto principal:
Doenças Inflamatórias Intestinais
Limite:
Humans
Idioma:
En
Revista:
Compr Ther
Ano de publicação:
1995
Tipo de documento:
Article
País de afiliação:
Estados Unidos